Informace o publikaci

Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results

Název česky Účinnost imatinib mesylatu u 72 Ph+ CML pacientů s přídavnými a bez přídavných chromozomálních změn: výsledky jednoho centra
Autoři

HOLZEROVÁ Milena FABER Edgar VESELOVSKÁ Jitka URBÁNKOVÁ Helena BALCÁRKOVÁ Jana ROŽMANOVÁ Šárka VOGLOVÁ Jaroslava MUŽÍK Jan CHROUST Karel INDRÁK Karel JAROŠOVÁ Marie

Rok publikování 2009
Druh Článek v odborném periodiku
Časopis / Zdroj Cancer Genetics and Cytogenetics
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Obor Onkologie a hematologie
Klíčová slova CML; imatinib; chromosomal changes
Popis Reported here are 72 previously treated Philadelphia chromosome-positive (Ph+) CML patients on imatinib (IM) therapy, with a focus on patients with additional chromosomal aberrations (CAs). At the start of IM treatment, 49 patients exhibited only the Ph chromosome (68%) and 23 patients (32%) had one or more additional CAs. There was no statistically significant difference in the overall survival of patients with additional CAs and patients with Ph as the sole abnormality. Patients in accelerated phase had significantly worse overall survival on IM, regardless of additional CAs. The present results confirm that the majority of previously treated Ph+ CML patients benefit from starting IM therapy, including patients with defined additional changes. In contrast, patients with complex karyotypes have poor prognosis, even with IM.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info